China FDA Clears Wosen Hib Vaccine In Infant’s Death
This article was originally published in PharmAsia News
Executive Summary
China's State FDA said a vaccine for pneumonia and meningitis was not at fault in the death of an infant girl in October. The agency said an investigation found nothing abnormal at the Wosen Biotechnology plant where the vaccine was produced. As a result, the drug bureau in Shandong where the death occurred lifted its ban on distribution and use of the hemophilus influenza type B vaccine. (Click here for more
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.